Halaman 1 dari 50 hasil
FIELD OF THE INVENTION
The present invention is directed to the administration to a warm blooded animal including humans of the combination of tegafur, uracil, and folinic acid and its administration with cyclophosphamide for the treatment of tumors.
BACKGROUND OF THE INVENTION
5--Fluorouracil
This invention relates to anti-cancer compositions, for delivering 5-fluorouracil to cancer tissues, of a cancer sensitive to 5-fluorouracil, in warm blooded animals.
In recent years, various excellent anti-cancer compositions have been introduced into use for the chemotherapy of malignant cancers
The present invention relates to certain enzyme inactivators which are useful in medicine, particularly cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
5-Fluorouracil has been used in cancer chemotherapy since 1957. sensitive
The present invention relates to certain enzyme inactivators which are useful in medicine, particularly cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
5-Fluorouracil has been used in cancer chemotherapy since 1957. sensitive
The present invention relates to certain enzyme inactivators which are useful in medicine, particularly cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
5-Fluorouracil has been used in cancer chemotherapy since 1957. Sensitive
TECHNICAL FIELD
This invention relates to a cancerous metastasis inhibitor which contains a uracil derivative having thymidine phosphorylase inhibiting activity.
BACKGROUND ART
Cancer treatments have achieved an innovative level of progress in recent years and, especially, an improvement in the
BACKGROUND OF THE INVENTION
A. DNCT and its Prior Uses
The goal of cancer therapy is to achieve a degree of selectivity that spares normal cells and destroys all malignant ones, since even a small number of remaining malignant cells can lead to recurrence, metastasis, and death. A two-component or
The goal of cancer therapy is to achieve a degree of selectivity that spares normal cells and destroys all malignant ones, since even a small number of remaining malignant cells can lead to recurrence, metastasis, and death. A two-component or binary system comprised of constituents that alone are
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
TECHNICAL FIELD
This invention relates to novel uracil derivatives having excellent inhibitory effects on human-derived thymidine phosphorylase, and also to antitumor effect potentiators and antitumor agents containing same.
BACKGROUND ART
Unnatural pyrimidine nucleosides showing antitumor
This is a 371 application of PCT/JP 96/00828 filed on Mar. 28, 1996.
TECHNICAL FIELD
This invention relates to novel uracil derivatives having excellent inhibitory effects on human-derived thymidine phosphorylase, and also to antitumor effect potentiators and antitumor agents containing
TECHNICAL FIELD
This invention relates to novel uracil derivatives having excellent inhibitory effects on human-derived thymidine phosphorylase, and also to antitumor effect potentiators and antitumor agents containing same.
BACKGROUND ART
Unnatural pyrimidine nucleosides showing antitumor
FIELD OF THE INVENTION
The present invention relates generally to the in vivo detection and measurement of the dose critical levels of certain anti-cancer drugs in blood, serum and other biological fluids, more specifically to the detection of such drugs using a probe DNA and still more specifically